Donor antigen-specific regulatory T cell administration to recipients of live donor kidneys: A ONE Study consortium pilot trial.

Humans Immunosuppressive Agents / pharmacology Tacrolimus / therapeutic use Mycophenolic Acid / therapeutic use Living Donors T-Lymphocytes, Regulatory Pilot Projects Kidney Steroids Graft Rejection / etiology
Tregs costimulation blockade regulatory T cells renal transplantation safety transplantation tolerance

Journal

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
ISSN: 1600-6143
Titre abrégé: Am J Transplant
Pays: United States
ID NLM: 100968638

Informations de publication

Date de publication:
Dec 2023
Historique:
received: 05 01 2023
revised: 26 05 2023
accepted: 20 06 2023
medline: 4 12 2023
pubmed: 9 7 2023
entrez: 8 7 2023
Statut: ppublish

Résumé

Regulatory T cells (Tregs) can inhibit cellular immunity in diverse experimental models and have entered early phase clinical trials in autoimmunity and transplantation to assess safety and efficacy. As part of the ONE Study consortium, we conducted a phase I-II clinical trial in which purified donor antigen reactive (dar)-Tregs (CD4

Identifiants

DOI: 10.1016/j.ajt.2023.06.012 PMID: 37422112
pubmed: 37422112
pii: S1600-6135(23)00543-9
doi: 10.1016/j.ajt.2023.06.012
pii:
doi:

Substances chimiques

Immunosuppressive Agents 0
Tacrolimus WM0HAQ4WNM
Mycophenolic Acid HU9DX48N0T
Steroids 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1872-1881

Informations de copyright

Crown Copyright © 2023. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: none.

Auteurs

Eva C Guinan (EC)

Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA. Electronic address: Eva_Guinan@dfci.harvard.edu.

Laura Contreras-Ruiz (L)

Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA. Electronic address: lcontrerasruiz15@gmail.com.

Kerry Crisalli (K)

Center for Transplantation Sciences, Massachusetts General Hospital, Boston, Massachusetts, USA. Electronic address: kcrisalli@mgh.harvard.edu.

Charles Rickert (C)

Center for Transplantation Sciences, Massachusetts General Hospital, Boston, Massachusetts, USA. Electronic address: chuckrickert@gmail.com.

Ivy Rosales (I)

Center for Transplantation Sciences, Massachusetts General Hospital, Boston, Massachusetts, USA. Electronic address: IROSALES@mgh.harvard.edu.

Robert Makar (R)

Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts, USA. Electronic address: rmakar@mgh.harvard.edu.

Robert Colvin (R)

Center for Transplantation Sciences, Massachusetts General Hospital, Boston, Massachusetts, USA. Electronic address: rbcolvin@mgh.harvard.edu.

Edward K Geissler (EK)

University Hospital Regensburg, Department of Surgery, Regensburg, Germany. Electronic address: edward.geissler@klinik.uni-regensburg.de.

Birgit Sawitzki (B)

Institute of Medical Immunology, Virchow - Klinikum, Berlin, Germany. Electronic address: birgit.sawitzki@bih-charite.de.

Paul Harden (P)

Oxford Transplant Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, UK. Electronic address: paul.harden@ouh.nhs.uk.

Qizhi Tang (Q)

Division of Transplantation, Department of Surgery, University of California, San Francisco, California, USA. Electronic address: qizhi.tang@ucsf.edu.

Giles Blancho (G)

Centre of Research in Transplantation and Immunology, Nantes University, Nantes, France. Electronic address: gilles.blancho@chu-nantes.fr.

Laurence A Turka (LA)

Center for Transplantation Sciences, Massachusetts General Hospital, Boston, Massachusetts, USA. Electronic address: lturka@gmail.com.

James F Markmann (JF)

Center for Transplantation Sciences, Massachusetts General Hospital, Boston, Massachusetts, USA. Electronic address: jmarkmann@mgh.harvard.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Donor antigen-specific regulatory T cell...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Effets physiologiques des médicaments › Facteurs immunologiques › Immunosuppresseurs › Donor antigen-specific regulatory T cell...
questionsmedicales.fr › Composés chimiques organiques › Lactones › Tacrolimus › Donor antigen-specific regulatory T cell...
questionsmedicales.fr › Lipides › Acides gras › Acide mycophénolique › Donor antigen-specific regulatory T cell...
questionsmedicales.fr › Personnes › Donneurs de tissus › Donneur vivant › Donor antigen-specific regulatory T cell...
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Leucocytes › Agranulocytes › Lymphocytes › Lymphocytes T › Sous-populations de lymphocytes T › Lymphocytes T régulateurs › Donor antigen-specific regulatory T cell...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Projets pilotes › Donor antigen-specific regulatory T cell...
questionsmedicales.fr › Appareil urogénital › Voies urinaires › Rein › Donor antigen-specific regulatory T cell...
questionsmedicales.fr › Composés polycycliques › Composés à cycles fusionnés › Stéroïdes › Donor antigen-specific regulatory T cell...
questionsmedicales.fr › Phénomènes du système immunitaire › Immunologie en transplantation › Réaction de l'hôte contre le greffon › Rejet du greffon › Donor antigen-specific regulatory T cell...